• Explore /
  • Poster
  • / Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Abstract Video & Slides Poster

Authors

null

Yasmin Karimi

University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Yasmin Karimi , Catherine Thieblemont , Hervé Ghesquieres , Chan Y Cheah , Michael Roost Clausen , David Cunningham , Wojciech Jurczak , Kim M. Linton , Martin Hutchings , Tycel Jovelle Phillips , Umar Farooq , Won Seog Kim , Minh H Dinh , Jagannath Ghosh , Rajash Pallai , Monica Wielgos-Bonvallet , Christian Eskelund , Pieternella Lugtenburg , Julie Vose

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Clinical Trial Registration Number

NCT03625037

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 7039)

DOI

10.1200/JCO.2024.42.16_suppl.7039

Abstract #

7039

Poster Bd #

22

Abstract Disclosures

Similar Posters

First Author: Yasmin Karimi

First Author: Michael Dickinson

First Author: Bei Hu

First Author: David Samuel DiCapua Siegel